Advertisement

A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective

  • Steve RyderEmail author
  • Kathleen Fox
  • Pratik Rane
  • Nigel Armstrong
  • Ching-Yun Wei
  • Sohan Deshpande
  • Lisa Stirk
  • Yi Qian
  • Jos Kleijnen
Systematic Review

Abstract

Introduction

There is a lack of comprehensive cost information for cardiovascular events since 2013.

Objective

A systematic review on the contemporary cost of cardiovascular events was therefore undertaken.

Methods

Methods complied with those recommended by the Cochrane Collaboration and the Centre for Reviews and Dissemination. Studies were unrestricted by language, were from 2013 to 23 December 2017, and included cost-of-illness data in adults with the following cardiovascular conditions: myocardial infarction (MI), stroke, transient ischaemic attack (TIA), heart failure (HF), unstable angina (UA), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or peripheral artery disease (PAD). Seven electronic databases were searched, namely Embase (Ovid), MEDLINE (Ovid), MEDLINE In-Process Citations and Daily Update (Ovid), NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) database, Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed. The included studies reported data from a variety of years (sometimes prior to 2013), so costs were inflated and converted to $US, year 2018 values, for standardization.

Results

After de-duplication, 29,945 titles and abstracts and then 403 full papers were screened; 82 studies (88 papers) were extracted. Year 1 average cost ranges were as follows: MI ($11,970 in Sweden to $61,864 in the USA), stroke ($10,162 in Spain to $46,162 in the USA), TIA ($6049 in Sweden to $25,306 in the USA), HF ($4456 in China to $49,427 in the USA), UA ($11,237 in Sweden to $31,860 in the USA), PCI ($17,923 in Italy to $45,533 in the USA), CABG ($17,972 in the UK to $76,279 in the USA). One Swedish study reported PAD costs in a format convertible to $US, 2018 values, with a mean annual cost of $15,565.

Conclusions

There was considerable unexplained variation in contemporary costs for all major cardiovascular events. One emerging theme was that average costs in the USA were considerably higher than anywhere else.

Notes

Acknowledgements

The authors acknowledge the help of the following contributors who assisted with screening, data extraction, and/or quality assessment: Regina Leadley, Sonia Garcia Gonzalez-Moral, Frank O’Neill (formerly Amgen Inc.), and Anna Bychenkova (Amgen Inc.). Medical writing support was provided by Cathryn M. Carter (Amgen Inc.).

Author Contributions

All of the listed authors conform to the requirements of the International Committee for Medical Journal Editors (ICMJE). SR, C-YW, SD, and NA designed the study, carried out the methodological framework, collected the data, reviewed the studies, and completed quality assessment. LS assisted in designing the study, developed and performed the original literature searches, and contributed to the writing and revision of the manuscript. SR, C-YW, and NA contributed to the writing, interpretation of the results, and revision of the manuscript. YQ, PR, JK, and KF participated in the study design, supervised the overall progress, and contributed to the interpretation of the results and revision of the manuscript. All authors read and approved the final manuscript. SR is the overall guarantor of this work.

Compliance with Ethical Standards

Funding

This study was funded by Amgen Inc. (Thousand Oaks, CA, USA).

Conflict of interest

Steve Ryder, Lisa Stirk, Nigel Armstrong, Ching-Yun Wei, and Sohan Deshpande are employees of Kleijnen Systematic Reviews (KSR) Ltd., an independent research company that was paid by Amgen Inc. to carry out this work. Jos Kleijnen is the owner of KSR Ltd. Pratik Rane and Yi Qian are employees and stock holders of Amgen Inc. Kathleen Fox serves as a consultant for Amgen Inc.

Human and animal rights

This manuscript reports on secondary research and does not directly report research on human participants and/or animals.

Informed consent

Informed consent and ethical approval were not required.

Supplementary material

40273_2019_795_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 19 kb)
40273_2019_795_MOESM2_ESM.docx (19 kb)
Supplementary material 2 (DOCX 18 kb)
40273_2019_795_MOESM3_ESM.docx (368 kb)
Supplementary material 3 (DOCX 368 kb)

References

  1. 1.
    World Health Organization. Cardiovascular diseases (CVDs). Fact sheet [Internet]. World Health Organization, 2016. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 11 Nov 2016.
  2. 2.
    Khavjou O, Phelps D, Leib A. Projections of cardiovascular disease prevalence and costs: 2015–2035. Technical report [Internet]. Research Triangle Park, NC: RTI International, 2016. https://healthmetrics.heart.org/projections-of-cardiovascular-disease/. Accessed 22 Jan 2019.
  3. 3.
    Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European cardiovascular disease statistics 2017 [Internet]. Brussels: European Heart Network, 2017. http://www.ehnheart.org/component/downloads/downloads/2452. Accessed 7 Mar 2017.
  4. 4.
    Nicholson G, Gandra SR, Halbert RJ, Richhariya A, Nordyke RJ. Patient-level costs of major cardiovascular conditions: a review of the international literature. Clinicoecon Outcomes Res. 2016;8:495–506.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ara R, Basarir H, Ward SE. Principles of health economic evaluations of lipid-lowering strategies. Curr Opin Lipidol. 2012;23(4):271–81.CrossRefPubMedGoogle Scholar
  6. 6.
    Wei CY, Quek RG, Villa G, Gandra SR, Forbes CA, Ryder S, et al. A systematic review of cardiovascular outcomes-based cost-effectiveness analyses of lipid-lowering therapies. Pharmacoeconomics. 2016;27:27.Google Scholar
  7. 7.
    Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR. Productivity losses associated with cardiovascular disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;10:10.Google Scholar
  8. 8.
    Gordois AL, Proudfoot EM, Paoli CJ, Gandra SR. Systematic review of productivity losses associated with cardiovascular disease in Europe. Value Health. 2015;18(7):A396 (Conference End: 20151111. Conference Publication:(var.pagings)).CrossRefPubMedGoogle Scholar
  9. 9.
    Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions [Internet]. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011. http://handbook.cochrane.org/. Accessed 23 Mar 2011.
  10. 10.
    Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking reviews in health care [Internet]. York: University of York, 2009. http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm. Accessed 23 Mar 2011.
  11. 11.
    Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bank of England. Inflation calculator. 2017. http://www.bankofengland.co.uk/education/Pages/resources/inflationtools/calculator/default.aspx. Accessed 3 Mar 2017.
  13. 13.
    Fxtop.com. Inflation calculator. 2017. http://fxtop.com/en/inflationcalculator.php. Accessed 3 Mar 2017.
  14. 14.
    Exchange Rates UK. US Dollar Exchange Rate. 2017. http://www.exchangeates.org.uk/US-Dollar-USD-currency-table.html. Accessed 3 Mar 2017.
  15. 15.
    Jakobsen M, Kolodziejczyk C, Fredslund EK, Poulsen PB, Dybro L, Johnsen SP. Societal costs of first-incident ischemic stroke in patients with atrial fibrillation—a Danish nationwide registry study. Value Health. 2016;19(4):413–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Jennum P, Iversen HK, Ibsen R, Kjellberg J. Cost of stroke: a controlled national study evaluating societal effects on patients and their partners. BMC Health Serv Res. 2015;15:466.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chevreul K, Durand-Zaleski I, Gouepo A, Fery-Lemonnier E, Hommel M, Woimant F. Cost of stroke in France. Eur J Neurol. 2013;20(7):1094–100.CrossRefPubMedGoogle Scholar
  18. 18.
    Blin P, Philippe F, Laurendeau C, Bouee S, Gourmelen J, Levy Bachelot L, et al. Increased costs due to myocardial infarction (MI) in France: an observational analysis using a claims database. Value Health. 2015;18(7):A386.CrossRefPubMedGoogle Scholar
  19. 19.
    Bonnet C, Millot I, Achouba A, Czekala M, Thonnelier C, Chauny J, et al. Heart failure management: a nationwide population-based cohort study using the french EGB database. Value Health. 2015;17(7):A405.CrossRefGoogle Scholar
  20. 20.
    Cotte FE, Chaize G, Gaudin AF, Samson A, Vainchtock A, Fauchier L. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace. 2016;18(4):501–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Abbas S, Ihle P, Hein R, Schubert I. Rehabilitation in geriatric patients after ischemic stroke—a comparison of 2 organisational systems in Germany using claims data of a statutory health insurance fund. Rehabilitation. 2013;52(6):375–82.CrossRefPubMedGoogle Scholar
  22. 22.
    Kritikou P, Spengos K, Zakopoulos N, Tountas Y, Yfantopoulos J, Vemmos K. Resource utilization and costs for treatment of stroke patients in an acute stroke unit in Greece. Clin Neurol Neurosurg. 2016;142:8–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Parissis J, Athanasakis K, Farmakis D, Boubouchairopoulou N, Mareti C, Bistola V, et al. Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. Int J Cardiol. 2015;180:46–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Stafylas P, Parissis J, Aletras V, Mavrodi A, Chatzopoulos S, Tsarouhas K, et al. Distribution and predictors of direct costs of acute heart failure in Greece: a social security system perspective. Eur Heart J. 2015;36:1112–3.Google Scholar
  25. 25.
    Stafylas P, Farmakis D, Kourlaba G, Giamouzis G, Tsarouhas K, Maniadakis N, et al. The heart failure pandemic: the clinical and economic burden in Greece. Int J Cardiol. 2017;227:923–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Hannon N, Daly L, Murphy S, Smith S, Hayden D, Ni Chroinin D, et al. Acute hospital, community, and indirect costs of stroke associated with atrial fibrillation: population-based study. Stroke. 2014;45(12):3670–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Roggeri A, Gnavi R, Dalmasso M, Rusciani R, Giammaria M, Anselmino M, et al. Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis. Crit Pathw Cardiol. 2013;12(4):204–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Corrao G, Ghirardi A, Ibrahim B, Merlino L, Maggioni AP. Burden of new hospitalization for heart failure: a population-based investigation from Italy. Eur J Heart Fail. 2014;16(7):729–36.CrossRefPubMedGoogle Scholar
  29. 29.
    Lucioni C, Mazzi S, Rossi E, Rielli R, Calabria S, Maggioni AP. Therapeutic strategies and health costs of patients admitted for a cardiovascular event in Italy. Glob Reg Health Technol Assess. 2016;3(2):80–91.Google Scholar
  30. 30.
    Maggioni AP, Cinconze E, Rossi E, De Rosa M, Esposito I, Martini N. Costs and outcomes of patients admitted for a cardiovascular ischemic disease in a large community setting of 2,989,512 subjects of the Italian National Health Service (NHS). Value Health. 2015;18(3):A137.CrossRefGoogle Scholar
  31. 31.
    Maggioni AP, Orso F, Calabria S, Rossi E, Cinconze E, Baldasseroni S, et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail. 2016;18(4):402–10.CrossRefPubMedGoogle Scholar
  32. 32.
    Soekhlal RR, Burgers LT, Redekop WK, Tan SS. Treatment costs of acute myocardial infarction in the Netherlands. Neth Heart J. 2013;21(5):230–5.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    van Eeden M, van Heugten C, van Mastrigt GA, van Mierlo M, Visser-Meily JM, Evers SM. The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke. BMJ Open. 2015;5(11):e008220.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Czech M, Opolski G, Zdrojewski T, Dubiel JS, Wizner B, Bolisega D, et al. The costs of heart failure in Poland from the public payer’s perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol. 2013;71(3):224–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Alvarez-Sabin J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, et al. Economic impact of patients admitted to stroke units in Spain. Eur J Health Econ. 2017;18(4):449–58.CrossRefPubMedGoogle Scholar
  36. 36.
    Alvarez Sabin J, Masjuan J, Casado MA, Mar J, Oliva J, Gonzalez-Rojas N. Costs in patients along first year poststroke in Spain. Value Health. 2013;16(7):A522.CrossRefGoogle Scholar
  37. 37.
    de Andres-Nogales F, Vivancos Mora J, Barriga Hernandez FJ, Diaz Otero F, Izquierdo Esteban L, Ortega-Casarrubios MA, et al. Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: the CODICE Study. Neurologia. 2015;30(9):536–44.CrossRefPubMedGoogle Scholar
  38. 38.
    Delgado JF, Oliva J, Llano M, Pascual-Figal D, Grillo JJ, Comin-Colet J, et al. Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain. Rev Esp Cardiol. 2014;67(8):643–50.CrossRefPubMedGoogle Scholar
  39. 39.
    Farre N, Vela E, Cleries M, Bustins M, Cainzos-Achirica M, Enjuanes C, et al. Medical resource use and expenditure in patients with chronic heart failure: a population-based analysis of 88 195 patients. Eur J Heart Fail. 2016;18(9):1132–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Ghatnekar O, Persson U, Asplund K, Glader EL. Costs for stroke in Sweden 2009 and developments since 1997. Int J Technol Assess Health Care. 2014;30(2):203–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Hallberg S, Gandra SR, Fox KM, Mesterton J, Banefelt J, Johansson G, et al. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data. Eur J Health Econ. 2016;17(5):591–601.CrossRefPubMedGoogle Scholar
  42. 42.
    Hallberg S, Banefelt J, Mesterton J, Gandra SR, Fox KM, Johansson G, et al. Health care costs associated with cardiovascular events in patients with hyperlipidemia—estimates from population-based register data in Sweden. Value Health. 2014;17(7):A492.CrossRefPubMedGoogle Scholar
  43. 43.
    Mejhert M, Lindgren P, Schill O, Edner M, Persson H, Kahan T. Long term health care consumption and cost expenditure in systolic heart failure. Eur J Intern Med. 2013;24(3):260–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Stalhammar J, Stern L, Linder R, Sherman S, Parikh R, Ariely R, et al. The burden of preserved ejection fraction heart failure in a real-world Swedish patient population. J Med Econ. 2014;17(1):43–51.CrossRefPubMedGoogle Scholar
  45. 45.
    Hasvold P, Nordanstig J, Kragsterman B, Kristensen T, Falkenberg M, Johansson S, et al. Long-term cardiovascular outcome, use of resources, and healthcare costs in patients with peripheral artery disease: results from a nationwide Swedish study. Eur Heart J Qual Care Clin Outcomes. 2018;4(1):10–17.CrossRefPubMedGoogle Scholar
  46. 46.
    Sozmen K, Pekel O, Yilmaz TS, Sahan C, Ceylan A, Guler E, et al. Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. Anatol J Cardiol. 2015;15(4):325–33.CrossRefPubMedGoogle Scholar
  47. 47.
    Ali AN, Howe J, Abdel-Hafiz A. Cost of acute stroke care for patients with atrial fibrillation compared with those in sinus rhythm. Pharmacoeconomics. 2015;33(5):511–20.CrossRefPubMedGoogle Scholar
  48. 48.
    Danese MD, Gleeson M, Kutikova L, Griffiths RI, Azough A, Khunti K, et al. Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open. 2016;6(8):e011805.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Luengo-Fernandez R, Yiin GS, Gray AM, Rothwell PM. Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke. 2013;8(5):308–14.CrossRefPubMedGoogle Scholar
  50. 50.
    Walker S, Asaria M, Manca A, Palmer S, Gale CP, Shah AD, et al. Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). Eur Heart J Qual Care Clin Outcomes. 2016;2(2):125–40.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Ogah OS, Stewart S, Onwujekwe OE, Falase AO, Adebayo SO, Olunuga T, et al. Economic burden of heart failure: investigating outpatient and inpatient costs in Abeokuta, Southwest Nigeria. PLoS One. 2014;9(11):e113032.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Fan GQ, Fu KL, Song M, Han L, Jin CW, Zhong M, et al. The impact of metabolic syndrome and hypertension on medical costs of patients with acute myocardial infarction at hospital. Clin Exp Hypertens. 2015;37(8):627–32.CrossRefPubMedGoogle Scholar
  53. 53.
    Fan GQ, Fu KL, Jin CW, Wang XZ, Han L, Wang H, et al. A medical costs study of older patients with acute myocardial infarction and metabolic syndrome in hospital. Clin Interv Aging. 2015;10:329–37.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Fu KL, Fan GQ, Han L, Wang XZ, Wang J, Wang YS, et al. Impact of type 2 diabetes mellitus on hospitalization costs in older patients with acute myocardial infarction. Clin Interv Aging. 2014;9:711–8.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Gu Q, Ma J, Li N, Yuan SW. Analysis of hospital expenditure and influencing factors of patients with acute myocardial infarction. Shanghai Jiao Tong Da Xue Xue Bao Yi Xue Ban. 2013;33(6):746–50.Google Scholar
  56. 56.
    Hu S, Zhan L, Liu B, Gao Y, Li Y, Tong R, et al. Economic burden of individual suffering from atrial fibrillation-related stroke in China. Value Health Reg Issues. 2013;2(1):135–40.CrossRefPubMedGoogle Scholar
  57. 57.
    Liu WW, Yang J, Yuan SW, Wei FQ, Ma J. Evaluation of hospitalization expense of patients with acute myocardial infarction before and after implementation of single disease quality control. Shanghai Jiao Tong Da Xue Xue Bao Yi Xue Ban. 2015;35(6):876–80.Google Scholar
  58. 58.
    Wang S, Petzold M, Cao J, Zhang Y, Wang W. Direct medical costs of hospitalizations for cardiovascular diseases in Shanghai, China: trends and projections. Medicine. 2015;94(20):e837.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Zhang H, Yuan X, Osnabrugge RL, Meng D, Gao H, Zhang S, et al. Influence of diabetes mellitus on long-term clinical and economic outcomes after coronary artery bypass grafting. Ann Thorac Surg. 2014;97(6):2073–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Huang J, Yin H, Zhang M, Ni Q, Xuan J. Understanding the economic burden of heart failure in China: impact on disease management and resource utilization. J Med Econ. 2017;20(5):549–53.CrossRefPubMedGoogle Scholar
  61. 61.
    Kwatra G, Kaur P, Toor G, Badyal DK, Kaur R, Singh Y, et al. Cost of stroke from a tertiary center in northwest India. Neurol India. 2013;61(6):627–32.CrossRefPubMedGoogle Scholar
  62. 62.
    Marfatia S, Monz B, Suvarna V, Bhure S, Sangole N. Treatment costs of stroke related to nonvalvular atrial fibrillation patients in India-a multicenter observational study. Value Health Reg Issues. 2014;3(1):205–10.CrossRefPubMedGoogle Scholar
  63. 63.
    Hosaka A, Miyata T, Onishi Y, Liao L, Zhang Q. Clinical and economic burden in patients with diagnosis of peripheral arterial disease in a claims database in Japan. Clin Ther. 2014;36(8):1223–1230.e4.CrossRefPubMedGoogle Scholar
  64. 64.
    Murata K, Hinotsu S, Sadamasa N, Yoshida K, Yamagata S, Asari S, et al. Healthcare resource utilization and clinical outcomes associated with acute care and inpatient rehabilitation of stroke patients in Japan. Int J Qual Health Care J Int Soc Qual Health Care. 2017;29(1):26–31.Google Scholar
  65. 65.
    Chang H, Yoon SS, Kwon YD. Categorized hospital charges of acute ischemic stroke according to trial of org 10172 in acute stroke treatment classification. Neurol India. 2013;61(6):633–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Lee H, Oh SH, Cho H, Cho HJ, Kang HY. Prevalence and socio-economic burden of heart failure in an aging society of South Korea. BMC Cardiovasc Disord. 2016;16(1):215.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Kim E, Kwon HY, Baek SH, Lee H, Yoo BS, Kang SM, et al. Medical costs in patients with heart failure after acute heart failure events: one-year follow-up study. J Med Econ. 2018;21(3):288–93.CrossRefPubMedGoogle Scholar
  68. 68.
    Lee HC, Chang KC, Huang YC, Hung JW, Chiu HH, Chen JJ, et al. Readmission, mortality, and first-year medical costs after stroke. J Chin Med Assoc. 2013;76(12):703–14.CrossRefPubMedGoogle Scholar
  69. 69.
    Ademi Z, Liew D, Zomer E, Gorelik A, Hollingsworth B, Steg PG, et al. Outcomes and excess costs among patients with cardiovascular disease. Heart Lung Circ. 2013;22(9):724–30.CrossRefPubMedGoogle Scholar
  70. 70.
    Chan YK, Tuttle C, Ball J, Teng TK, Ahamed Y, Carrington MJ, et al. Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue. BMC Health Serv Res. 2016;16(1):501.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Chan Y, Ball J, Teng T, Tuttle C, Ahamed Y, Carrington M, et al. Increasing clinical and economic burden of heart failure among older Australians. Heart Lung Circ. 2015;24:S446.CrossRefGoogle Scholar
  72. 72.
    Gloede TD, Halbach SM, Thrift AG, Dewey HM, Pfaff H, Cadilhac DA. Long-term costs of stroke using 10-year longitudinal data from the North East Melbourne Stroke Incidence Study. Stroke. 2014;45(11):3389–94.CrossRefPubMedGoogle Scholar
  73. 73.
    Bagai A, Cantor WJ, Tan M, Tong W, Lamy A, Fitchett D, et al. Clinical outcomes and cost implications of routine early PCI after fibrinolysis: one-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) study. Am Heart J. 2013;165(4):630–637.e2.CrossRefPubMedGoogle Scholar
  74. 74.
    Hollander MJ, Kadlec H. Incentive-based primary care: cost and utilization analysis. Perm J. 2015;19(4):46–56.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Baron SJ, House J, Cohen DJ. Impact of coronary calcification on clinical outcomes and health care related costs among elderly patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2016;4(4 Suppl 1):S17.CrossRefGoogle Scholar
  76. 76.
    Ben-Josef G, Ott LS, Spivack SB, Wang C, Ross JS, Shah SJ, et al. Payments for acute myocardial infarction episodes-of-care initiated at hospitals with and without interventional capabilities. Circ Cardiovasc Qual Outcomes. 2014;7(6):882–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Bonafede MM, Johnson BH, Paoli CJ, Gandra SR. Annual fatal and non-fatal cardiovascular event costs among non-elderly commercially insured adults with hyperlipidemia in the United States. Value Health. 2016;19(3):A46.CrossRefGoogle Scholar
  78. 78.
    Borah BJ, Roger VL, Mills RM, Weston SA, Anderson SS, Chamberlain AM. Association between atrial fibrillation and costs after myocardial infarction: a community study. Clin Cardiol. 2015;38(9):548–54.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Chang DW, Tseng CH, Shapiro MF. Rehospitalizations following sepsis: common and costly. Crit Care Med. 2015;43(10):2085–93.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Chinthammit C, Coull BM, Nimworapan M, Bhattacharjee S. Co-occurring chronic conditions and economic burden among stroke survivors in the United States: a propensity score-matched analysis. J Stroke Cerebrovasc Dis. 2016;25:25.CrossRefGoogle Scholar
  81. 81.
    Fox KM, Wang L, Gandra SR, Quek RG, Li L, Baser O. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study. BMC Cardiovasc Disord. 2016;16:13.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Henk HJ, Paoli CJ, Gandra SR. A retrospective study to examine healthcare costs related to cardiovascular events in individuals with hyperlipidemia. Adv Ther. 2015;32(11):1104–16.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Ho PM, O’Donnell CI, Bradley SM, Grunwald GK, Helfrich C, Chapko M, et al. 1-year risk-adjusted mortality and costs of percutaneous coronary intervention in the Veterans Health Administration: insights from the VA CART Program. J Am Coll Cardiol. 2015;65(3):236–42.CrossRefPubMedGoogle Scholar
  84. 84.
    Kazi DS, Ben-Yehuda O, Bonafede M, Hernandez JB, Machacz SF, Hlatky MA. Economic burden of angina and chest pain following percutaneous coronary intervention: a real-world analysis of multi-payer US claims. Circulation. 2014;130(Suppl 2):A16951.Google Scholar
  85. 85.
    Likosky DS, Zhou W, Malenka DJ, Borden WB, Nallamothu BK, Skinner JS. Growth in medicare expenditures for patients with acute myocardial infarction: a comparison of 1998 through 1999 and 2008. JAMA Intern Med. 2013;173(22):2055–61.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, et al. Real-world costs of ischemic stroke by discharge status. Curr Med Res Opin. 2017;33(2):371–78.CrossRefPubMedGoogle Scholar
  87. 87.
    Punekar RS, Fox KM, Richhariya A, Fisher MD, Cziraky M, Gandra SR, et al. Burden of first and recurrent cardiovascular events among patients with hyperlipidemia. Clin Cardiol. 2015;38(8):483–91.CrossRefPubMedGoogle Scholar
  88. 88.
    Reed Chase M, Friedman HS, Navaratnam P, Heithoff K, Simpson RJ. Resource use and costs in high-risk symptomatic peripheral artery disease patients with diabetes and prior acute coronary syndrome: a retrospective analysis. Postgrad Med. 2016;128(2):170–9.CrossRefPubMedGoogle Scholar
  89. 89.
    Chase MR, Friedman HS, Navaratnam P, Heithoff K, Simpson RJ. Comparative assessment of medical resource use and costs associated with patients with symptomatic peripheral artery disease in the United States. J Manag Care Spec Pharm. 2016;22(6):667–75.PubMedGoogle Scholar
  90. 90.
    Simpson AN, Bonilha HS, Kazley AS, Zoller JS, Ellis C. Marginal costing methods highlight the contributing cost of comorbid conditions in medicare patients: a quasi-experimental case-control study of ischemic stroke costs. Cost Eff Resour Alloc. 2013;11(1):29.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Solomon MD, Leong TK, Sung SH, Inveiss A, Hernandez JB, White RM, et al. Cost and utilization among patients after incident percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(15 Suppl 1):B181.CrossRefGoogle Scholar
  92. 92.
    Ward A, Alvarez P, Vo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ. 2014;17(3):176–83.CrossRefPubMedGoogle Scholar
  93. 93.
    Yang E, Stokes M, Johansson S, Mellstrom C, Magnuson E, Cohen DJ, et al. Clinical and economic outcomes among elderly myocardial infarction survivors in the United States. Cardiovasc Ther. 2016;26:26.Google Scholar
  94. 94.
    Yoon J, Fonarow GC, Groeneveld PW, Teerlink JR, Whooley MA, Sahay A, et al. Patient and facility variation in costs of VA heart failure patients. JACC Heart Fail. 2016;4(7):551–8.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Teich V, Piha T, Fahham L, Squiassi HB, Paloni Ede M, Miranda P, et al. Acute coronary syndrome treatment costs from the perspective of the supplementary health system. Arq Bras Cardiol. 2015;105(4):339–44.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Da Silva G, Colosimo FC, Sousa AG, Piotto RF, Castilho V. Coronary artery bypass graft surgery cost coverage by the Brazilian Unified health system (SUS). Rev Bras Cir Cardiovasc. 2017;32(4):253–9.Google Scholar
  97. 97.
    Dennis R, Rojas M, Tamayo D, Rodriguez V, Brophy J, Castro H. Costs associated with hospital admission for heart failure in two hospitals in the city of Bogota, Colombia. Value Health. 2013;16(3):A190.CrossRefGoogle Scholar
  98. 98.
    Dedov II, Kontsevaya AV, Shestakova MV, Belousov YB, Balanova JA, Khudyakov MB, et al. Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation. Diabetes Mellit. 2016;19(6):518–27.CrossRefGoogle Scholar
  99. 99.
    Kim H, Kim J, Ku H, Lee E, Ko S. Estimating the economic burden of heart failure patients in Korea. Value Health. 2016;19(7):A865.CrossRefGoogle Scholar
  100. 100.
    Roggeri DP, Roggeri A, Rossi E, Cinconze E, De Rosa M, Maggioni AP, et al. Direct healthcare costs and resource consumption after acute coronary syndrome: a real-life analysis of an Italian subpopulation. Eur J Prev Cardiol. 2014;21(9):1090–6.CrossRefPubMedGoogle Scholar
  101. 101.
    Brouwer ED, Watkins D, Olson Z, Goett J, Nugent R, Levin C. Provider costs for prevention and treatment of cardiovascular and related conditions in low- and middle-income countries: a systematic review. BMC Public Health. 2015;15:1183.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Kaur P, Kwatra G, Kaur R, Pandian JD. Cost of stroke in low and middle income countries: a systematic review. Int J Stroke. 2014;9(6):678–82.CrossRefPubMedGoogle Scholar
  103. 103.
    Brennan VK, Colosia AD, Copley-Merriman C, Mauskopf J, Hass B, Palencia R. Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. J Med Econ. 2014;17(7):469–80.CrossRefPubMedGoogle Scholar
  104. 104.
    Lavoie L, Khoury H, Welner S, Briere JB. Burden and prevention of adverse cardiac events in patients with concomitant chronic heart failure and coronary artery disease: a literature review. Cardiovasc Ther. 2016;34(3):152–60.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Schmid T. Costs of treating cardiovascular events in Germany: a systematic literature review. Health Econ Rev. 2015;5(1):27.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Ali AN, Abdelhafiz A. Clinical and economic implications of AF related stroke. J Atr Fibrillation. 2016;8(5):85–92.Google Scholar
  107. 107.
    de Pouvourville G. Cost of ischemic stroke management in France (French). Arch Cardiovasc Dis Suppl. 2016;8(2):161–8.Google Scholar
  108. 108.
    Nicholson G, Paoli CJ, Gandra SR. Systematic literature review of direct health care costs for cardiovascular events among European patients with dyslipidemia or high cardiovascular risk. Value Health. 2015;18(7):A387.CrossRefPubMedGoogle Scholar
  109. 109.
    Gray AM, Murphy J, Altman DG, Benedetto U, Campbell H, Flather M, et al. One-year costs of bilateral or single internal mammary grafts in the arterial revascularisation trial. Heart (British Cardiac Society). 2017;103(21):1719–26.Google Scholar
  110. 110.
    Echouffo-Tcheugui JB, Bishu KG, Fonarow GC, Egede LE. Trends in health care expenditure among US adults with heart failure: the medical expenditure panel survey 2002–2011. Am Heart J. 2017;186:63–72.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Kleijnen Systematic Reviews LtdYorkUK
  2. 2.Strategic Healthcare Solutions LLCAikenUSA
  3. 3.Amgen IncThousand OaksUSA
  4. 4.School for Public Health and Primary CareMaastricht UniversityMaastrichtThe Netherlands

Personalised recommendations